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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not the use
of TENS is safe and effective in preventing and treating PHN.
STUDY DESIGN: Two randomized controlled trials and one retrospective observational study
that were published in peer-reviewed journals after 2006 in the English language were reviewed.
DATA SOURCES: Studies were found in the PubMed database and selected based on relevance
to the research question and whether they evaluated patient oriented outcomes.
OUTCOMES MEASURED: Prevention of PHN, determined by absence or presence of
symptoms, and reduction of pain due to PHN, using a visual analog scale (VAS).
RESULTS: In the first RCT, Barbarisi et al showed that TENS therapy along with pregabalin
caused a statistically significant reduction in pain (p < 0.02) compared to pregabalin plus placebo
device. Stepanovic et al studied the use of TENS in preventing PHN and found that it was
significantly better than antiviral treatment (p = 0.001). In the retrospective observational study
by Kolsek, 0% of patients treated with TENS therapy during acute HZ developed PHN,
compared to 28.6% of patients treated with antivirals.
CONCLUSIONS: The use of TENS is both safe and effective in preventing and treating
postherpetic neuralgia.
KEYWORDS: transcutaneous electrical nerve stimulation, postherpetic neuralgia
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INTRODUCTION
Herpes Zoster (HZ) is a dermatologic condition caused by the reactivation of Varicella
Zoster Virus (VZV). It affects approximately 30% of the population, leading to 1 million new
cases diagnosed each year1. The virus remains dormant in dorsal root ganglia following varicella
infection, and is believed to reactivate due to reduced cellular immunity associated with
immunocompromising states such as stress and increased age2. HZ is a clinical diagnosis
characterized by a vesicular eruption in a dermatomal distribution, most commonly on the trunk.
It is a self-limiting, viral infection lasting up to a few weeks with relatively low incidences of
morbidity and mortality. Up to 30% of patients, however, go on to develop post-herpetic
neuralgia (PHN)3,4,5,6.
PHN, the most common complication of HZ, is characterized by moderate to severe
burning, tingling, and/or hyperesthesia in a dermatomal pattern that lasts months to years, and is
occasionally lifelong. The pathophysiology of PHN is not completely understood but is believed
to be multifactorial, involving the necrosis, fibrosis, and destruction of afferent nerve fibers to
the spinal cord2.
Many cases of HZ are treated with antivirals such as acyclovir, valacyclovir, and
brivudine. Antiviral therapy has been shown to decrease severity and duration of HZ, but no
treatment has been shown to decrease the incidence of PHN3,6. The current first line treatments
for PHN are tricyclic antidepressants like amitriptyline, and anti-seizure drugs like gabapentin
and pregabalin7. Topical agents such as capsaicin cream and lidocaine are also frequently used
for more mild cases or patients that do not want systemic therapy. Although the use of opioids
for chronic pain is controversial, their efficacy in treating PHN has been shown in a small
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number of trials and these agents are still commonly prescribed7. Less commonly used methods
for refractory pain include glucocorticoid injections and botulinum toxin injections7.
The estimated annual health care cost of HZ in the United States is $1.1 billion8. Patients
who go on to develop PHN have health care costs that are 4 - 7 times higher than patients who do
not develop the complication, costing up to $11,147 per case9. The costs associated with HZ and
subsequent PHN can partly be explained by the difficulty in treating neuropathic pain and the
need for chronic treatment.
While pharmacologic therapies remain the mainstay of treatment for PHN, these drugs
are not always effective in reducing pain and create a challenge for physicians and patients. A
non-pharmacologic intervention, transcutaneous electrical nerve stimulation (TENS), has been
shown to effectively reduce pain in various acute and chronic conditions3,7,10. TENS is the
process by which electrodes placed on the skin produce an electrical current that activates
various receptors leading to pain reduction. This application has been shown to provide analgesia
both peripherally and centrally by activating opioid, serotonin, muscarinic, and alpha-2
noradrenergic receptors3,10. TENS may be safe and effective in decreasing pain caused by PHN,
and possibly in preventing PHN altogether.
With the aging population, the number of patients experiencing HZ is expected to
increase, leading to an increased number of patients with PHN. New modalities of pain relief that
are both safe and effective will become increasingly important for the PA profession, and
providers as a whole, as the number of patients requiring treatment increases.
OBJECTIVE
The objective of this systematic review is to determine whether or not the use of TENS is
safe and effective in treating and preventing PHN.
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METHODS
This paper evaluates two randomized controlled trials (RCTs) and one retrospective
observational study. All three studies compared the use of TENS to a visually-matched placebo
device, another traditional treatment modality, or no treatment. The primary outcomes measured
were prevention of PHN and reduction of pain. Articles were searched through the PubMed
database and selected based on relevance to the research question and whether or not patientoriented outcomes were used. Keywords used included “transcutaneous electrical nerve
stimulation” and “postherpetic neuralgia”. Articles published in English in peer-reviewed
journals after 2006 were evaluated. The demographics and specific characteristics of each study
are represented in Table 1.

Table 1. Demographics and characteristics of included studies.
Study

Type

# Pts

Age
in
years
50-80

Inclusion Criteria

Exclusion Criteria

W/D

Interventions

Barbarisi,
2010

RCT

30

PHN > 3 mo; locations
of pain at cervical,
thoracic, lumbar, or
sacral root ganglions;
VAS score of at least
60 mm

0

Pregabalin
(300mg and
600mg doses)
+ TENS
therapy

102

68.9
+/16.6

Patients in the
electronic medical
record of a health
center in Slovenia
with clinical diagnosis
of HZ

0

TENS therapy
alone,
antiviral
therapy alone,
TENS +
antiviral

222

69 +/17.31

Patients in a primary
health care office that

Hypersensitivity to
pregabalin;
neoplastic,
hematologic, hepatic,
renal disease;
immunodeficiency;
occipital, trigeminal
HZ; alcohol misuse
w/in 2 y; serious
psychological
condition
Patients that moved
away whose later
records could not be
analyzed; patients
that were
hospitalized; patients
with ocular
involvement
Patients with HZ in
the ocular or genital
region;

Kolsek,
2012

Retrospective,
observational

Stepanovic,
2016

RCT

0

TENS therapy
alone,
antiviral
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presented with clinical
diagnosis of HZ

immunocompromised
patients, patients with
chronic diseases;
patients with previous
neuropathic pain

therapy alone,
TENS +
antiviral

OUTCOMES MEASURED
The primary outcomes measured in all three studies were prevention of PHN in patients
with HZ and reduction of pain due to PHN. In the study by Barbarisi et al, the primary measure
of reduction of pain due to PHN was a change in baseline of a visual analog scale (VAS), “0”
being no pain and “100 mm” being worst possible pain. Over the four week experiment patients
filled out the VAS for pain at each visit. The authors also measured sleep interference due to pain
using a questionnaire that patients completed at each visit. Treatment groups for this study
included use of pregabalin (300mg dose) + TENS therapy, pregabalin (600mg dose) + TENS
therapy, and two groups with each respective dose of pregabalin + TENS placebo.
In the study by Stepanovic et al, the primary outcome measured was prevention of PHN
using TENS therapy. Patients with clinical diagnosis of HZ were treated either with TENS
therapy alone, TENS + antiviral therapy, antiviral therapy alone, or no intervention. To
determine incidence of PHN, the authors had patients record the presence or absence of the
following symptoms over a 6 month period: spontaneous feelings of pain, allodynia,
hyperalgesia, and/or paresthesia. The authors also analyzed adverse events between treatment
groups.
In the retrospective observational study by Kolsek, the primary outcome measured was
prevention of PHN. The author evaluated this outcome using medical records of patients treated
for HZ in three outpatient family practices. The treatment groups included TENS therapy alone,
antiviral therapy alone, TENS + antiviral therapy, and the control group included patients who
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received no therapy or who received any of the therapies but presented to treatment after 72
hours of rash eruption. The author analyzed the use of analgesics among treatment groups,
incidence of PHN, and adverse events related to any of the treatment types.
RESULTS
The study by Barbarisi et al was a randomized, placebo-controlled trial that included 30
patients receiving either pregabalin (300 or 600 mg) with TENS therapy or pregabalin (300 mg
or 600 mg) with a visually matched TENS placebo device. The statistical analyses used by the
authors include mean change in baseline and ANOVA. The patients receiving TENS therapy at
either dose of pregabalin showed statistically significant reductions in pain compared to groups
receiving respective doses of pregabalin and TENS placebo (p < 0.02 for both doses of
pregabalin). The results of the study are shown in Table 2. Compliance to drug therapy was not
reported, however compliance to TENS therapy was maintained as each patient received therapy
on location at the test site.

Table 2. Summary of reduction in pain from baseline from Barbarisi et al.
Treatment
600 mg Pregabalin + TENS
600 mg Pregabalin + Placebo
300 mg Pregabalin + TENS
300 mg Pregabalin + Placebo

Reduction in Pain from Baseline
40%
16%
30%
10%

In the RCT by Stepanovic et al, the authors evaluated the efficacy of TENS therapy,
antivirals, TENS therapy + antivirals, or no treatment on the prevention of PHN. To determine
the effect of each treatment group on development of PHN, they performed a logistic regression,
using presence of PHN and treatment type as the dependent and independent variables,
respectively. They reported a statistically significant correlation between the treatment types and
PHN (p = 0.001); the odds for developing PHN were significantly lower in patients treated with
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TENS therapy alone, with a numbers needed to treat (NNT) of 4. The odds of developing PHN
using any of the other treatments were not statistically significant. The results of this study are
summarized in Table 3. The authors report that the only adverse events of the trial were bacterial
skin infections and no serious complications were reported. There was no statistical difference in
adverse events between treatment groups (p = 0.128). Compliance to drug therapy was not noted,
but TENS therapy was given on location at the test site to maintain compliance.

Table 3. Summary of results of logistic regression on prediction of PHN using Odds Ratio (OR)
from Stepanovic et al.
Treatment
TENS therapy

OR (95% CI)
0.15 (0.05; 0.47)

p
0.001

NNT
4

The article by Kolsek was a retrospective observational study that examined the medical
records of 102 patients treated for HZ in outpatient family practices. A Chi squared test was used
to analyze differences in prevalence of PHN between treatment groups. The rate of patients with
PHN in the TENS therapy group was 0%, the antiviral group was 28.6%, antiviral + TENS
therapy group was 20.8%, and the control group without therapy had a rate of 14.3%. TENS
therapy alone had the greatest statistically significant decrease in rate of PHN with p = 0.024.
Using this data, 4 patients would need to be treated with TENS therapy in order to prevent 1
patient from developing PHN (NNT=4), as compared to traditional antiviral therapy. The results
of this study are summarized in Table 4. Adverse events were not reported numerically but the
author claimed that the only complication included secondary bacterial infection and the
difference between treatment groups was not significant. Compliance to drug therapy was not
noted. The author also does not indicate whether TENS therapy was done in the office or at
home, and again does not mention compliance.
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Table 4. Summary of treatment effects of TENS therapy on preventing PHN from Kolsek study.
Relative Risk Reduction (RRR)
0.4

Absolute Risk Reduction (ARR)
28.6%

NNT
4

DISCUSSION
The treatment of PHN remains a difficult task for providers. Despite vaccination efforts,
the incidence of HZ has increased within recent years, likely due to a shift in demographics and
the aging population1. With increases in HZ occurrence, the number of patients developing PHN
is going to increase, with older adults having the greatest chance of developing the
complication3,4,5.
TENS therapy has been shown to be effective in reducing acute and chronic pain in some
studies, yet its use in certain conditions remains controversial and meta analyses on its efficacy
continue to have conflicting results7,10,11. In the Barbarisi et al study analyzed in this systematic
review, TENS therapy along with standard treatment methods was shown to significantly
decrease pain due to PHN compared to standard treatment methods alone. These results may
imply that multiple treatment modalities should be used when treating chronic pain. A
shortcoming to this study was that the physician administering the TENS device or TENS
placebo device was not blinded. The authors explain how blinding would be impossible as the
administering physician needed to explain to patients that they would either experience an
electrical tingling sensation or nothing at all. The sample size was also very small in this study,
with each treatment group containing between 6 and 8 patients. It is also important to note that
compliance to drug therapy was not reported in the study.
While antivirals decrease the duration and intensity of HZ, they have no effect on the
prevalence of PHN3,4. Vaccination has been shown to decrease incidence of HZ and therefore
PHN6, but with the aging population the incidence of PHN continues to be up to 30%3. The use
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of TENS therapy during HZ has been shown to decrease the incidence of PHN4,5,11. In this
systematic review, two studies assessing the efficacy of TENS therapy in reducing PHN were
analyzed. In the RCT by Stepanovic et al, TENS therapy alone was shown to have a significant
decrease on the incidence of PHN, when compared to antiviral therapy given alone or in addition
to TENS therapy. The pathophysiology behind the combination of antivirals and TENS therapy
not reducing PHN is unknown and needs to be investigated further, but these findings are
consistent with other trials4,11. The retrospective observational study by Kolsek showed that
TENS therapy during HZ resulted in a 100% decrease in PHN incidence and was significantly
better in preventing PHN than antivirals. The study has some limitations because it is
retrospective and observational. One could speculate that patients receiving only TENS therapy
had less severe cases of HZ, which has been linked to a decreased chance of developing PHN5,11.
Another limitation with this study is that the placebo effect could have played a major role.
Patients in the treatment group receiving TENS therapy all came from the same practicing
physician who the author states had always used TENS to treat HZ. If that was a common
practice by that physician, then it is likely that he would have told patients the device decreases
pain and has been shown to be effective, possibly influencing results. Both of these studies show
that TENS therapy is more effective in reducing development of PHN compared to antivirals, yet
they do not comment on drug compliance. Some of the antivirals used are dosed 3-5 times per
day, which could easily have led to missed doses and affected outcomes.
Harmful side effects and adverse events due to TENS therapy have not been reported; the
only contraindications to its use are implanted pacemakers and malignant skin lesions5,10. The
studies in this systematic review reported no adverse events due to TENS therapy and no
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significant difference between secondary bacterial infections caused by HZ vesicles in treatment
or control groups4,5.
CONCLUSION
TENS therapy is safe, inexpensive, and easy for patients to use, leading to its growing
popularity in treating many acute and chronic pain conditions. The studies analyzed in this
systematic review provide evidence suggesting TENS therapy is safe and effective in treating
and preventing PHN. TENS therapy alone has been shown to decrease the incidence of PHN, but
the mechanism behind this is unclear4,5,10. It is also unclear why the use of TENS therapy in
combination with antivirals does not decrease the incidence of PHN. Both of these are areas of
further research that could be investigated as TENS therapy becomes more commonly used.
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